[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 199
Citations 0
Comment & Response
October 2016

Study on the Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell CarcinomaNot a Case-Control Study

Author Affiliations
  • 1Institute of Clinical Medicine, University of Oslo, Oslo, Norway
JAMA Dermatol. 2016;152(10):1172. doi:10.1001/jamadermatol.2016.2427

To the Editor In the May 2016 issue of JAMA Dermatology, Mohan et al1 report an increased risk of cutaneous squamous cell carcinoma (CSCC) after vismodegib therapy for basal cell carcinoma (BCC).1 They collected data from a cohort of 55 patients with BCC treated with vismodegib and compared the risk of CSCC with that in a cohort of 125 patients with BCC not treated with vismodegib. The authors present the study as a case-control study, which it is not.

First Page Preview View Large
First page PDF preview
First page PDF preview